8 results about "Methylone" patented technology

The present disclosure relates to amorphous forms of (6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (Compound A) and processes for preparing amorphous forms of Compound A. The present disclosure also provides pharmaceutical dosage forms comprising the amorphous forms of Compound A as an active pharmaceutical ingredient and methods of preparing the pharmaceutical dosage forms.

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

The present invention relates to a crystalline form of an imidazo[1,2-a]pyridine compound, and more specifically to a monohydrate crystalline form, crystalline form A, and crystalline form B serving as an active pharmaceutical ingredient of azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone and as an intermediate of a final salt addition compound, and a method for preparing same. The monohydrate crystalline form, crystalline form A, and crystalline form B of the compound of chemical formula I according to the present invention have excellent stability under high-humidity or high-temperature conditions, and thus can be usefully applied to the formulation of pharmaceuticals.

The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

In one aspect, the present disclosure provides a method of synthesis for methylone HCl, with 3,4-methylenedioxypropiophenone (MDP) as the starting material. In another aspect, the present disclosure provides stereoisomers of methylone. In another aspect, the present disclosure provides phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described prodrug form allows slow / sustained / controlled delivery of the parent phenethylamines or cathinones into the blood system in a manner that would increase the duration of therapeutic efficacy.

The invention relates to an application of a (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative in preparation of a medicine for resisting bone resorption and inhibiting osteoclast differentiation, and the (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative X-1 and X-4 inhibit formation of TRAP + mononuclear osteoclast precursor cells, and the (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative X-1 and the (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative X-4 inhibit formation of TRAP + mononuclear osteoclast precursor cells. And the (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivatives X-2, X-3 and X-5 selectively block the further differentiation of the TRAP + osteoclast precursor cells into the mature osteoclast. The (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative has the beneficial effects that the (1-phenyl-1H-pyrazole-3, 4, 5-triyl) tri (phenyl ketone) derivative provided by the invention can be used as a novel candidate drug molecule of an inhibitor for resisting bone resorption and osteoclast differentiation, and is used for developing a novel inhibitor for osteoclast differentiation.

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.